Glycated hemoglobin, reported as HbA 1c , is a biochemical marker that is routinely used in the management of diabetes mellitus to monitor long-term glycemic control and assess the risk of developing complications. [1] [2] [3] The presence of hemoglobin (Hb) C or S trait has been shown to affect the accuracy of some HbA 1c assays. [4] [5] [6] [7] [8] [9] In 2004, there were 23.5 million non-Hispanic blacks aged 18 years or older in the United States, 10 of whom at least 10% have HbC or HbS trait. 11 The prevalence of diabetes mellitus, diagnosed and undiagnosed, in non-Hispanic black men is 13.0% and in non-Hispanic black women is 16.3%. 12 This works out to between 305,000 and 383,000 people who have diabetes mellitus and HbC or HbS trait.
Because of the number of patients with diabetes mellitus who could potentially be affected by inaccurate HbA 1c results due to interference by the presence of HbC or HbS trait, we continued our earlier investigations and evaluated the effects of HbC and HbS traits on the results of 14 commercial HbA 1c methods that use ion exchange chromatography (6 methods), immunoassay (5 methods), boronate affinity (2 methods), and enzymatic (1 method) techniques. Nearly all of the methods evaluated in this study have not been previously evaluated in a rigorous manner for interference from the presence of HbC or HbS trait. This is the first time that we have evaluated an enzymatic assay for HbA 1c for the possibility of interference by Hb variants. We reexamined 2 ion exchange methods to see whether they currently have interference issues because we have previously shown there may be lot-to-lot variability in susceptibility to interference by Hb traits for some HbA 1c methods. 8, 9 
Materials and Methods
Whole blood samples from people homozygous for HbA (n = 68) and heterozygous for HbC or HbS (n = 58 and n = 72, respectively) were collected in EDTA tubes. The clinical site for sample collection was located in an urban area with a high proportion of African American patients so there would be a good opportunity to identify samples with HbC or HbS traits. After routine clinical testing had been completed, Hb variants were identified by inspection of chromatograms obtained with a VARIANT analyzer (Bio-Rad Laboratories, Hercules, CA) using the Beta Thal Short Program run according to manufacturer's instructions. No additional confirmatory testing of samples containing Hb variants was performed. Aliquots of these samples that had HbA 1c results between 4% and 14% (0.04-0.14) were analyzed within 7 days by using the Afinion AS100 method (Axis Shield, Norton, MA) and stored at -70°C for analysis by the other methods. Not all samples were analyzed by every method. Studies with samples from human subjects were approved by the University of Utah Institutional Review Board (Salt Lake City).
Samples were analyzed by the following assays and instruments: Afinion AS100; ultra 2 All assays were performed according to the manufacturers' instructions. The CLC 330 boronate affinity method (Primus Diagnostics) was used as the comparative method in a National Glycohemoglobin Standardization Program (NGSP) Network Laboratory with in-house calibrator materials. This method has previously been shown to be unaffected by the presence of HbC and HbS traits. 13 Results for all methods were reported as NGSP HbA 1c equivalents.
For each method, results for each type of sample (homozygous HbA, heterozygous HbC, and heterozygous HbS) were compared with results from the CLC330 method. An overall test of coincidence of 2 least-square linear regression lines was performed with SAS software (SAS Institute, Cary, NC) to determine whether the presence of HbC or HbS trait produced a statistically significant difference (P < .01) in results relative to the comparative method. To determine whether the presence of HbC or HbS trait produced clinically significant effects on the HbA 1c results, we chose evaluation limits of 6% and 9% based on recommendations by the American Diabetes Association of an upper reference limit of 6% (0.06) and a general goal of 7% (0.07) and the Diabetes Control and Complications Trial conventional treatment group mean HbA 1c of approximately 9% (0.09). Deming regression analysis was performed to estimate the average bias at 6% (0.06) and 9% (0.09) HbA 1c . After correcting for possible calibration bias by comparing results from the homozygous HbA sample group, evaluation of method bias attributable to the presence of HbC or HbS trait was performed. A relative deviation of greater than 10% (ie, 0.6% at 6% HbA 1c and 0.9% at 9% HbA 1c ) compared with the homozygous HbA sample group was used to define a clinically significant difference. This 10% relative difference has been used in previous studies. [7] [8] [9] 14 
Results
Information on the number of samples analyzed by each method for each sample type and the average biases at 6% (0.06) and 9% (0.09) HbA 1c due to the presence of HbC and HbS traits are shown zTable 1z. We observed no clinically significant differences attributable to the presence of HbC or HbS trait for any assay except the Olympus AU400. The Olympus HbA 1c method demonstrated a clinically significant positive bias for HbC and HbS trait samples at both evaluation limits of 6% (0.06) and 9% (0.09). The package insert for this method indicates that samples containing HbC or HbS trait can have result elevations of 40% due to the presence of these variants. An abstract indicated that samples containing HbC and HbS traits showed maximum positive biases of 43% and 32%, respectively, when analyzed by the Olympus method compared with the VARIANT II method. 15 This information is consistent with our data.
Box plots for each combination of sample type and assay are shown zFigure 1z. The presence of HbC trait produced statistically significant differences (P < .01) for all methods except the Afinion AS100, D-10 Extended, ultra 2 , and VARIANT II TURBO methods. The presence of HbS trait produced statistically significant differences only for the G7, Microgenics, Olympus, Pointe Scientific, and VARIANT II methods. One other interesting observation is that the G7, Microgenics, and Pointe Scientific methods showed an increased range of differences with the comparative method for samples containing HbS trait compared with the differences seen for samples homozygous for HbA and those containing HbC trait.
Discussion
Some previous studies have shown clinically significant effects on HbA 1c measurements by the presence of HbC or HbS trait with certain ion exchange methods, unlike the present study in which all of these methods showed clinically nonsignificant effects. The G7 ion exchange method showed statistically but not clinically significant negative biases for samples with HbC and HbS traits, which is in agreement with the findings of a previous study. 14 However, in the present study, the net negative bias for the G7 method with samples containing the HbS trait estimated from Deming regression analysis at the 9% (0.09) HbA 1c evaluation limit was close to the limit of -0.9%. The VARIANT ion exchange method for HbA 1c has been previously reported to exhibit positive bias with samples containing the HbS trait. 8, 9 In the present study, it exhibited a slight positive bias at the 6% (0.06) evaluation limit that was not clinically significant. The VARIANT II method has been previously shown to exhibit positive clinically significant biases for samples containing both HbC and HbS traits, but our results in the present study show a net positive bias with VARIANT II that is not clinically significant. 9, 14 We have not yet evaluated the newly released VARIANT II NU reagents. Differences between the results obtained in this study and previous studies are consistent with lot-to-lot variability or intentional improvements in the response of ion exchange methods to interference by Hb variants. Of the 5 immunoassays evaluated in the present study, the COBAS INTEGRA 800 method exhibited negative net biases estimated from Deming regression analysis for HbC and HbS traits at both evaluation limits, whereas the Olympus method exhibited positive net biases for both traits at both limits. The previous reagents used on the COBAS INTEGRA 800 had shown a clinically significant positive bias with samples containing the HbC or HbS trait. 4, 7, 8 The data from the current generation 2 assay on the COBAS INTEGRA 800 agree with another recent study indicating no clinically significant bias for either trait. 16 For all immunoassay methods examined in this study, only 1, the Olympus method, demonstrated clinically significant effects from HbC and HbS traits. For both HbC and HbS traits, HbA 1c was overestimated, which could lead to overly rigorous glycemic control with consequent hypoglycemia. Attention to the effects of Hb variants on the results of HbA 1c methods is necessary to ensure accurate results for people who have an Hb variant and diabetes mellitus. Furthermore, for methods that do not allow the operator to identify the presence of an Hb variant, including boronate affinity, enzymatic, and immunoassay, if the method is affected to a clinically significant extent by a particular Hb variant that will be encountered in the patient population being tested, it may be necessary to determine the Hb phenotype of each patient with diabetes mellitus. If a patient with an Hb variant that interferes with the routine HbA 1c method is identified, all samples from that patient will need to be tested by an alternative method that is not prone to interference by the particular Hb variant. Alternatively, instead of determining the Hb phenotype of each patient, a comment could be added to each HbA 1c result indicating that the possibility of an Hb variant interference should be considered if the HbA 1c result is not consistent with the mean plasma glucose level estimated by the patient's self-monitoring results or clinical estimates of glycemic control.
